stockrow
Friday 6 November 2026
Export SKIN’s income statement to Excel — free account
SkinHealth Systems Inc.
SKIN Consumer Defensive Household & Personal Products
SkinHealth Systems Inc.’s revenue for fiscal 2025 (year ended December 2025) was $300.8 million, down 10.0% from fiscal 2024.
- Revenue
- −2.10%
- EPS
- −112.5%
- Free cash flow
- +19.1%
- Total debt
- −33.1%
Quarter to September 2026, against a year earlier
15.79
5.44
+52.56%
Follow SKIN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.58 | 0.38 | 0.31 | 0.28 | |
P/FCF ratio |
5.43 | 4.89 | 5.39 | 4.47 | |
P/Operating CF |
11.56 | (20.48) | 33.60 | 7.25 | |
P/B ratio |
2.88 | 2.06 | 1.62 | 1.46 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.02 | 0.86 | 0.79 | 1.09 | |
EV/EBITDA |
37.57 | 14.25 | 9.51 | 13.10 | |
EV/Operating CF |
8.20 | 8.76 | 10.42 | 13.37 | |
EV/FCF |
9.51 | 10.90 | 13.75 | 17.25 | |
Quick Ratio |
1.37 | 1.45 | 1.34 | 1.90 | |
Current Ratio |
1.66 | 1.79 | 1.76 | 2.89 | |
Net Debt/EBITDA |
20.18 | 30.77 | 14.15 | 0.00 | |
Debt/Assets |
72.91% | 72.74% | 70.95% | 62.45% | |
Debt/Equity |
5.97 | 6.23 | 6.21 | 4.36 | |
Asset Turnover |
0.51 | 0.52 | 0.58 | 0.65 | |
Operating CF/Net income |
(1.88) | 0.84 | (1.00) | (12.68) | |
Capex/Depreciation |
(0.22) | (0.26) | (0.19) | 0.00 | |
Interest Coverage |
0.03 | (0.28) | 0.57 | 0.79 | |
Research and Development Expense of Revenue |
2.04% | 1.70% | 1.95% | 2.40% | |
Selling, General and Administrative Expense of Revenue |
62.15% | 69.54% | 61.51% | 58.56% | |
Intangible Assets out of Total Assets |
0.32 | 0.34 | 0.32 | 0.40 | |
Share Based Compensation of Revenue |
4.35% | 3.20% | 4.01% | 2.08% | |
Graham Net Nets |
(0.74) | (1.23) | (1.51) | (1.61) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(5.04%) | (4.49%) | (31.77%) | (34.92%) | |
Free Cash Flow Yield |
18.40% | 20.46% | 18.54% | 22.39% | |
Revenue per Share |
13.04 | 10.16 | 11.13 | 0.00 | |
Operating CF per Share |
2.40 | (0.87) | 0.41 | 0.00 | |
Capex per Share |
(0.22) | (0.26) | (0.19) | 0.00 | |
Free Cash Flow per Share |
2.19 | (1.13) | 0.23 | 0.00 | |
Cash per Share |
36.82 | 31.98 | 31.80 | 0.00 | |
Shareholders Equity per Share |
9.66 | 8.65 | 8.58 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.66 | 8.65 | 8.58 | 0.00 | |
Free Cash Flow |
13.81 | (7.20) | 1.47 | 10.20 | |
Working Capital |
123.24 | 122.49 | 127.04 | 131.75 | |
Capital Expenditures |
(1.38) | (1.65) | (1.20) | (1.06) | |
Net Current Asset Value |
(129.23) | (140.30) | (135.76) | (131.72) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 45.62 | |
Capex to Sales |
0.02 | 0.03 | 0.02 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 11.81 | |
| Other line items | |||||
Average Receivables |
25.95 | 21.89 | 23.38 | 22.85 | |
Average Payables |
18.79 | 19.51 | 19.51 | 16.19 | |
Average Inventory |
58.56 | 56.66 | 53.01 | 51.20 | |
Average Assets |
592.74 | 573.53 | 497.07 | 446.35 | |
Average Common Equity |
56.43 | 50.65 | 64.79 | 60.71 |
Columns are period end dates · fundamentals updated 5 Nov 2026